• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Artiva Biotherapeutics Inc.

    5/18/26 7:31:55 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ARTV alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Artiva Biotherapeutics, Inc.

    (Name of Issuer)


    Common Stock, $0.0001 par value per share

    (Title of Class of Securities)




    04317A107

    (CUSIP Number)
    05/11/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    VIKING GLOBAL INVESTORS LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,604,166.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,604,166.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,604,166.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Parent GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,604,166.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,604,166.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,604,166.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,822,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,822,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,822,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,822,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,822,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,822,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Illiquid Investments Sub-Master LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,822,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,822,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,822,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Vintage IV GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    781,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    781,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    781,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Vintage IV Portfolio GP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    781,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    781,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    781,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.6 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Viking Global Opportunities Vintage IV (Aggregator) LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    781,250.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    781,250.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    781,250.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.6 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    HALVORSEN OLE ANDREAS
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NORWAY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,604,166.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,604,166.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,604,166.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    CUSIP Number(s):
    04317A107


    1Names of Reporting Persons

    Shabet Rose Sharon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    2,604,166.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    2,604,166.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    2,604,166.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    5.4 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  See Item 4


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Artiva Biotherapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    5505 Morehouse Drive, Suite 100, San Diego, California 92121
    Item 2. 
    (a)Name of person filing:

    Viking Global Investors LP ("VGI"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("VGOP"), Viking Global Opportunities Vintage IV GP LLC ("VGOVIV GP"), Viking Global Opportunities Vintage IV Portfolio GP LLC ("VGOVIV Portfolio GP"), Viking Global Opportunities Vintage IV (Aggregator) LP ("VGOVIV"), O. Andreas Halvorsen and Rose S. Shabet (collectively, the "Reporting Persons")
    (b)Address or principal business office or, if none, residence:

    The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
    (c)Citizenship:

    VGI is a Delaware limited partnership; Opportunities Parent, Opportunities GP, Opportunities Portfolio GP, VGOVIV GP and VGOVIV Portfolio GP are Delaware limited liability companies; VGOP and VGOVIV are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and Rose S. Shabet is a citizen of the United States.
    (d)Title of class of securities:

    Common Stock, $0.0001 par value per share
    (e)CUSIP Number(s):

    04317A107
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    VGI: 2,604,166 VGI provides managerial services to VGOP and VGOVIV. VGI has the authority to dispose of and vote the shares of Common Stock that VGOP and VGOVIV directly own. VGI does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Act"), VGI may be deemed to beneficially own the shares of Common Stock that VGOP and VGOVIV directly own. VGI beneficially owns 2,604,166 shares of Common Stock consisting of 1,822,916 and 781,250 shares of Common Stock directly owned by VGOP and VGOVIV, respectively. Opportunities Parent: 2,604,166 Opportunities Parent is the sole member of Opportunities GP, which has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP (which consists of the shares of Common Stock that VGOP directly owns), and is the sole member of VGOVIV GP, which has the authority to dispose of and vote the shares of Common Stock controlled by VGOVIV Portfolio GP (which consists of the shares of Common Stock that VGOVIV directly owns). Opportunities Parent does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Act, Opportunities Parent may be deemed to beneficially own the shares of Common Stock that VGOP and VGOVIV directly own. Opportunities Parent beneficially owns 2,604,166 shares of Common Stock consisting of 1,822,916 and 781,250 shares of Common Stock directly owned by VGOP and VGOVIV, respectively. Opportunities GP: 1,822,916 Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock that VGOP directly owns. In addition, Opportunities GP is the general partner of each of Viking Global Opportunities Intermediate LP, Viking Global Opportunities III LP, and Viking Global Opportunities LP. Opportunities GP does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Act, Opportunities GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns. Opportunities GP beneficially owns 1,822,916 shares of Common Stock consisting of 1,822,916 shares of Common Stock directly owned by VGOP. Opportunities Portfolio GP: 1,822,916 Opportunities Portfolio GP serves as the general partner of VGOP and has the authority to dispose of and vote the shares of Common Stock that VGOP directly owns. Opportunities Portfolio GP does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Act, Opportunities Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOP directly owns. Opportunities Portfolio GP beneficially owns 1,822,916 shares of Common Stock consisting of 1,822,916 shares of Common Stock directly owned by VGOP. VGOP: 1,822,916 VGOP has the authority to dispose of and vote the 1,822,916 shares of Common Stock that it owns, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOP. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOP. VGOVIV GP: 781,250 VGOVIV GP serves as the sole member of VGOVIV Portfolio GP and has the authority to dispose of and vote the shares of Common Stock controlled by VGOVIV Portfolio GP, which consists of the shares of Common Stock that VGOVIV directly owns. In addition, VGOVIV GP is the general partner of each of Viking Global Opportunities Vintage IV (Offshore) LP and Viking Global Opportunities Vintage IV (Onshore) LP. VGOVIV GP does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Act, VGOVIV GP may be deemed to beneficially own the shares of Common Stock that VGOVIV directly owns. VGOVIV GP beneficially owns 781,250 shares of Common Stock consisting of 781,250 shares of Common Stock directly owned by VGOVIV. VGOVIV Portfolio GP: 781,250 VGOVIV Portfolio GP serves as the general partner of VGOVIV and has the authority to dispose of and vote the shares of Common Stock that VGOVIV directly owns. VGOVIV Portfolio GP does not directly own any shares of Common Stock. Based on Rule 13d-3 under the Act, VGOVIV Portfolio GP may be deemed to beneficially own the shares of Common Stock that VGOVIV directly owns. VGOVIV Portfolio GP beneficially owns 781,250 shares of Common Stock consisting of 781,250 shares of Common Stock directly owned by VGOVIV. VGOVIV: 781,250 VGOVIV has the authority to dispose of and vote the 781,250 shares of Common Stock that it directly owns, which power may be exercised by VGOVIV Portfolio GP, and by VGI, an affiliate of VGOVIV Portfolio GP, which provides managerial services to VGOVIV. Viking Global Opportunities Vintage IV (Offshore) LP (a Cayman Islands exempted limited partnership) and Viking Global Opportunities Vintage IV (Onshore) LP (a Delaware limited partnership) invest substantially all of their assets in VGOVIV. O. Andreas Halvorsen and Rose S. Shabet: 2,604,166 Mr. Halvorsen and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (general partner of VGI) and Opportunities Parent, have shared authority to dispose of and vote the shares of Common Stock beneficially owned by VGI and Opportunities Parent. Neither Mr. Halvorsen nor Ms. Shabet directly owns any shares of Common Stock. Based on Rule 13d-3 under the Act, each may be deemed to beneficially own the shares of Common Stock that VGOP and VGOVIV directly own. Each of Mr. Halvorsen and Ms. Shabet beneficially owns 2,604,166 shares of Common Stock consisting of 1,822,916 and 781,250 shares of Common Stock directly owned by VGOP and VGOVIV, respectively.
    (b)Percent of class:

    The percentages set forth herein are based on 48,588,198 shares of Common Stock expected to be outstanding following the Issuer's underwritten offering that closed on May 11, 2026, as reported in the Issuer's prospectus on Form 424B5, filed with the Securities and Exchange Commission (the "Commission") on May 8, 2026. VGI: 5.4% Opportunities Parent: 5.4% Opportunities GP: 3.8% Opportunities Portfolio GP: 3.8% VGOP: 3.8% VGOVIV GP: 1.6% VGOVIV Portfolio GP: 1.6% VGOVIV: 1.6% O. Andreas Halvorsen and Rose S. Shabet: 5.4%
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOVIV GP: 0 VGOVIV Portfolio GP: 0 VGOVIV: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (ii) Shared power to vote or to direct the vote:

    VGI: 2,604,166 Opportunities Parent: 2,604,166 Opportunities GP: 1,822,916 Opportunities Portfolio GP: 1,822,916 VGOP: 1,822,916 VGOVIV GP: 781,250 VGOVIV Portfolio GP: 781,250 VGOVIV: 781,250 O. Andreas Halvorsen and Rose S. Shabet: 2,604,166

     (iii) Sole power to dispose or to direct the disposition of:

    VGI: 0 Opportunities Parent: 0 Opportunities GP: 0 Opportunities Portfolio GP: 0 VGOP: 0 VGOVIV GP: 0 VGOVIV Portfolio GP: 0 VGOVIV: 0 O. Andreas Halvorsen and Rose S. Shabet: 0

     (iv) Shared power to dispose or to direct the disposition of:

    VGI: 2,604,166 Opportunities Parent: 2,604,166 Opportunities GP: 1,822,916 Opportunities Portfolio GP: 1,822,916 VGOP: 1,822,916 VGOVIV GP: 781,250 VGOVIV Portfolio GP: 781,250 VGOVIV: 781,250 O. Andreas Halvorsen and Rose S. Shabet: 2,604,166

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The response to Item 4 is incorporated by reference herein.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    VIKING GLOBAL INVESTORS LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Parent GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Illiquid Investments Sub-Master LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Vintage IV GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Vintage IV GP LLC (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Vintage IV Portfolio GP LLC
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Vintage IV Portfolio GP LLC (1)(2)
    Date:05/18/2026
     
    Viking Global Opportunities Vintage IV (Aggregator) LP
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Viking Global Opportunities Vintage IV (Aggregator) LP (1)(2)
    Date:05/18/2026
     
    HALVORSEN OLE ANDREAS
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of O. Andreas Halvorsen (1)
    Date:05/18/2026
     
    Shabet Rose Sharon
     
    Signature:/s/ Scott M. Hendler
    Name/Title:Scott M. Hendler on behalf of Rose S. Shabet (2)
    Date:05/18/2026

    Comments accompanying signature:  (1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES VINTAGE IV GP LLC, VIKING GLOBAL OPPORTUNITIES VINTAGE IV PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES VINTAGE IV (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, VIKING GLOBAL OPPORTUNITIES VINTAGE IV GP LLC, VIKING GLOBAL OPPORTUNITIES VINTAGE IV PORTFOLIO GP LLC and VIKING GLOBAL OPPORTUNITIES VINTAGE IV (AGGREGATOR) LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).
    Exhibit Information

    EXHIBIT A - JOINT FILING AGREEMENT

    Get the next $ARTV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ARTV

    DatePrice TargetRatingAnalyst
    6/11/2025$12.00Buy
    H.C. Wainwright
    12/30/2024$20.00Buy
    H.C. Wainwright
    8/13/2024$21.00Buy
    Jefferies
    8/13/2024$23.00Overweight
    Cantor Fitzgerald
    8/13/2024Buy
    TD Cowen
    8/13/2024$18.00Outperform
    Wedbush
    8/13/2024$23.00Buy
    Needham
    More analyst ratings

    $ARTV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/28/26 4:34:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SVP, Research and Development Raymon Heather sold $27,879 worth of shares (3,095 units at $9.01), decreasing direct ownership by 2% to 148,228 units (SEC Form 4) to satisfy withholding tax

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/19/26 9:52:54 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Chief Tech Operations Officer Horan Christopher sold $63,073 worth of shares (7,002 units at $9.01), decreasing direct ownership by 2% to 293,450 units (SEC Form 4) (for withholding tax)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/19/26 9:52:09 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    The $13 Million Company Teaching the Immune System to Hunt Cancer

    Issued on behalf of GT Biopharma, Inc. (NASDAQ:GTBP)Three drugs in human trials. A platform licensed from one of the world's top cancer-research universities. A market cap smaller than a Manhattan apartment. For investors willing to look where almost no one is looking, GT Biopharma is the kind of asymmetric setup that biotech is built on.NEW YORK, May 29, 2026 /CNW/ -- USA News Group Market Commentary - Start with the number that makes everyone do a double take. As of mid-May 2026, GT Biopharma (NASDAQ:GTBP) carried a market capitalization of roughly $13 million. Thirteen million. That is not a typo, and it is not a shell company. It is a clinical-stage immuno-oncology company with three sep

    5/29/26 9:00:00 AM ET
    $ARTV
    $FATE
    $GTBP
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Artiva Biotherapeutics to Participate in the 2026 Jefferies Global Healthcare Conference

    SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced that Artiva management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Thursday, June 4, 2026, at 9:20 am EDT. To access the audio webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Artiva's website. The archived audio webcast will remain available for replay on Artiva's website for 90 days. About Arti

    5/28/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Multiple AlloNK® Data Presentations at EULAR 2026 Congress, Including Late-Breaking Oral Presentation Highlighting Clinical Efficacy Comparable to Autologous CAR T-Cell Therapy in Rheumatologic Diseases

    Late-breaking oral presentation to highlight AlloNK + rituximab clinical responses comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including 71% ACR50 response in refractory rheumatoid arthritis (RA) patients with at least six months of follow-up with no patients relapsing or requiring new immunomodulatory agentsOral presentation to feature positive experience in the first patient with severe Sjögren disease treated with AlloNK + rituximabPoster presentations to highlight deep, consistent B-cell depletion comparable to CD19 CAR T-cell therapies and a favorable safety profile in immune-mediated diseasesLive post-meeting webcast to be held Monday, June 8

    5/19/26 4:05:00 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright resumed coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright resumed coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $12.00

    6/11/25 7:52:47 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    H.C. Wainwright initiated coverage on Artiva Biotherapeutics with a new price target

    H.C. Wainwright initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $20.00

    12/30/24 7:13:58 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Artiva Biotherapeutics with a new price target

    Jefferies initiated coverage of Artiva Biotherapeutics with a rating of Buy and set a new price target of $21.00

    8/13/24 7:24:03 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    SEC Filings

    View All

    SEC Form 8-K filed by Artiva Biotherapeutics Inc.

    8-K - Artiva Biotherapeutics, Inc. (0001817241) (Filer)

    5/19/26 8:07:26 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    5/18/26 7:53:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Artiva Biotherapeutics Inc.

    144 - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    5/18/26 7:51:16 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Gc Corp. bought $16,499,992 worth of shares (1,432,291 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/28/26 4:34:23 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. bought $74,999,992 worth of shares (6,510,416 units at $11.52) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    5/13/26 5:45:56 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Director Ra Capital Management, L.P. converted options into 1,058,282 shares, acquired $4,709,207 worth of shares (461,687 units at $10.20) and bought $99,999,996 worth of shares (8,333,333 units at $12.00) (SEC Form 4)

    4 - Artiva Biotherapeutics, Inc. (0001817241) (Issuer)

    7/24/24 4:27:11 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Leadership Updates

    Live Leadership Updates

    View All

    Artiva Biotherapeutics Appoints Veteran Biotech Executive and Drug Developer Diego Miralles, M.D., as President and Head of Research and Development

    Veteran biotechnology executive with more than 20 years of leadership experience spanning research, clinical development, commercialization and company building Proven track record advancing multiple therapeutics from discovery through FDA approval and commercialization, including PREZISTA® and INTELENCE® SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with debilitating autoimmune diseases, today announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings

    5/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Thad Huston as Chief Financial Officer and Award of Inducement Grant

    SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Thad Huston as Chief Financial Officer. Mr. Huston brings proven expertise in capital allocation, operational execution and global commercialization to support Artiva as it advances AlloNK in autoimmune diseases and continues building an organization positioned for long-term value creation. "We are delighted to welcome Thad to Artiva as he brings strong late-stage development and comme

    2/24/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Artiva Biotherapeutics Announces Appointment of Elaine Sorg to Board of Directors

    SAN DIEGO, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) (Artiva), a clinical-stage biotechnology company whose mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers, today announced the appointment of Elaine Sorg to its Board of Directors. Ms. Sorg brings more than 35 years of executive leadership and commercial experience in the biopharmaceutical industry to Artiva, including leading the commercialization of major immunology therapies such as HUMIRA® (adalimumab) and RINVOQ® (upadacitinib) for rheumatoid arthritis. "We are thrilled to welcome Elaine to Artiva's board at such an imp

    2/19/26 8:00:00 AM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ARTV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Artiva Biotherapeutics Inc.

    SC 13G/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    11/14/24 4:56:18 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13D/A filed by Artiva Biotherapeutics Inc.

    SC 13D/A - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    9/3/24 4:18:05 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Artiva Biotherapeutics Inc.

    SC 13G - Artiva Biotherapeutics, Inc. (0001817241) (Subject)

    8/1/24 7:00:07 PM ET
    $ARTV
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care